Cannabis for the Treatment of Epilepsy: an Update - PubMed (original) (raw)
Review
Cannabis for the Treatment of Epilepsy: an Update
Tyler E Gaston et al. Curr Neurol Neurosci Rep. 2018.
Abstract
Purpose of review: For millennia, there has been interest in the use of cannabis for the treatment of epilepsy. However, it is only recently that appropriately powered controlled studies have been completed. In this review, we present an update on the research investigating the use of cannabidiol (CBD), a non-psychoactive component of cannabis, in the treatment of epilepsy.
Recent findings: While the anticonvulsant mechanism of action of CBD has not been entirely elucidated, we discuss the most recent data available including its low affinity for the endocannabinoid receptors and possible indirect modulation of these receptors via blocking the breakdown of anandamide. Additional targets include activation of the transient receptor potential of vanilloid type-1 (TRPV1), antagonist action at GPR55, targeting of abnormal sodium channels, blocking of T-type calcium channels, modulation of adenosine receptors, modulation of voltage-dependent anion selective channel protein (VDAC1), and modulation of tumor necrosis factor alpha release. We also discuss the most recent studies on various artisanal CBD products conducted in patients with epilepsy in the USA and internationally. While a high percentage of patients in these studies reported improvement in seizures, these studies were either retrospective or conducted via survey. Dosage/preparation of CBD was either unknown or not controlled in the majority of these studies. Finally, we present data from both open-label expanded access programs (EAPs) and randomized placebo-controlled trials (RCTs) of a highly purified oral preparation of CBD, which was recently approved by the FDA in the treatment of epilepsy. In the EAPs, there was a significant improvement in seizure frequency seen in a large number of patients with various types of treatment-refractory epilepsy. The RCTs have shown significant seizure reduction compared to placebo in patients with Dravet syndrome and Lennox-Gastaut syndrome. Finally, we describe the available data on adverse effects and drug-drug interactions with highly purified CBD. While this product is overall well tolerated, the most common side effects are diarrhea and sedation, with sedation being much more common in patients taking concomitant clobazam. There was also an increased incidence of aspartate aminotransferase and alanine aminotransferase elevations while taking CBD, with many of the patients with these abnormalities also taking concomitant valproate. CBD has a clear interaction with clobazam, significantly increasing the levels of its active metabolite N-desmethylclobazam in several studies; this is felt to be due to CBD's inhibition of CYP2C19. EAP data demonstrate other possible interactions with rufinamide, zonisamide, topiramate, and eslicarbazepine. Additionally, there is one case report demonstrating need for warfarin dose adjustment with concomitant CBD. Understanding of CBD's efficacy and safety in the treatment of TRE has expanded significantly in the last few years. Future controlled studies of various ratios of CBD and THC are needed as there could be further therapeutic potential of these compounds for patients with epilepsy.
Keywords: Cannabidiol; Cannabis; Dravet syndrome; Efficacy; Epilepsy; Interactions; Lennox-Gastaut syndrome; Mechanism of action; Tetrahydrocannabinol.
Similar articles
- Cannabinoids in treatment-resistant epilepsy: A review.
O'Connell BK, Gloss D, Devinsky O. O'Connell BK, et al. Epilepsy Behav. 2017 May;70(Pt B):341-348. doi: 10.1016/j.yebeh.2016.11.012. Epub 2017 Feb 8. Epilepsy Behav. 2017. PMID: 28188044 Review. - Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, Brigo F. Lattanzi S, et al. CNS Drugs. 2021 Mar;35(3):265-281. doi: 10.1007/s40263-021-00807-y. Epub 2021 Mar 22. CNS Drugs. 2021. PMID: 33754312 Free PMC article. - Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox-Gastaut syndrome.
Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J, Hung P, Lerner JT, Sankar R. Hussain SA, et al. Epilepsy Behav. 2015 Jun;47:138-41. doi: 10.1016/j.yebeh.2015.04.009. Epub 2015 Apr 29. Epilepsy Behav. 2015. PMID: 25935511 - The proposed mechanisms of action of CBD in epilepsy.
Gray RA, Whalley BJ. Gray RA, et al. Epileptic Disord. 2020 Jan 1;22(S1):10-15. doi: 10.1684/epd.2020.1135. Epileptic Disord. 2020. PMID: 32053110 - Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Devinsky O, et al. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Epilepsia. 2014. PMID: 24854329 Free PMC article. Review.
Cited by
- Review of pharmacogenetics of antiseizure medications: focusing on genetic variants of mechanistic targets.
Lin CH, Ho CJ, Chen SY, Lu YT, Tsai MH. Lin CH, et al. Front Pharmacol. 2024 Aug 20;15:1411487. doi: 10.3389/fphar.2024.1411487. eCollection 2024. Front Pharmacol. 2024. PMID: 39228521 Free PMC article. Review. - SRF Facilitates Transcriptional Inhibition of Gem Expression by m6A Methyltransferase METTL3 to Suppress Neuronal Damage in Epilepsy.
Li L, Liu Z. Li L, et al. Mol Neurobiol. 2024 Aug 27. doi: 10.1007/s12035-024-04396-x. Online ahead of print. Mol Neurobiol. 2024. PMID: 39190265 - Medical Cannabis Prescription Practices and Quality of Life in Thai Patients: A Nationwide Prospective Observational Cohort Study.
Stienrut P, Pongpirul K, Phutrakool P, Savigamin C, Sermsaksasithorn P, Chanhom O, Jeamjumrus P, Pongchaichanon P, Nootim P, Soisamrong M, Chuthaputti A, Wanaratna K, Thaneerat T. Stienrut P, et al. Med Cannabis Cannabinoids. 2024 Jul 17;7(1):125-137. doi: 10.1159/000540153. eCollection 2024 Jan-Dec. Med Cannabis Cannabinoids. 2024. PMID: 39144529 Free PMC article. - Traumatic Brain Injury Outcomes After Recreational Cannabis Use.
Szaflarski JP, Szaflarski M. Szaflarski JP, et al. Neuropsychiatr Dis Treat. 2024 Apr 3;20:809-821. doi: 10.2147/NDT.S453616. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 38586307 Free PMC article. - Cannabinoids in Periodontology: Where Are We Now?
Carmona Rendón Y, Garzón HS, Bueno-Silva B, Arce RM, Suárez LJ. Carmona Rendón Y, et al. Antibiotics (Basel). 2023 Nov 30;12(12):1687. doi: 10.3390/antibiotics12121687. Antibiotics (Basel). 2023. PMID: 38136721 Free PMC article. Review.
References
- Brain. 2016 Aug;139(Pt 8):2164-81 - PubMed
- J Epilepsy Res. 2017 Dec 31;7(2):61-76 - PubMed
- Cell Death Dis. 2013 Dec 05;4:e949 - PubMed
- Drug Metab Pharmacokinet. 2013;28(4):332-8 - PubMed
- Epilepsy Behav. 2017 May;70(Pt B):328-333 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials